Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study1

Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study1

Show other versions (1)

Background and objective: The Anemia Working Group of ERBP in 2010 recommended a target hemoglobin (Hb) level in the range of 11-12 g/dL, without intentionally exceeding 13g/dL during the treatment with erythropoiesis stimulating agents (ESAs). This study evaluated if there was a clinical impact of...

Full description

Bibliographic Details
Main Authors:	Alberto Martínez-Castelao, Aleix Cases, Alberto Torre Carballada, Javier Torralba Iranzo, Josep Bronsoms, Martí Vallès-Prats, Daniel Torán Monserrat, Elisabet Masso Jimenez
Format:	Article
Language:	English
Published:	Elsevier 2015-03-01
Series:	Nefrología (English Edition)
Subjects:	Anemia Chronic kidney disease Hemoglobin Erythropoiesis-stimulating agents Observational Study
Online Access:	http://www.sciencedirect.com/science/article/pii/S2013251415000115

Similar Items

Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study1
by: Alberto Martínez-Castelao, et al.
Published: (2015-03-01)

Simply red: A novel spectrophotometric erythroid proliferation assay as a tool for erythropoiesis and erythrotoxicity studies
by: Daniela Boehm, et al.
Published: (2014-12-01)

Variability in Hemoglobin Levels and the Factors Associated with Mortality in Hemodialysis Patients: A 78-Month Follow-Up Study
by: Natalino Salgado Filho, et al.
Published: (2021-01-01)

Application of innovative hemocytometric parameters and algorithms for improvement of microcytic anemia discrimination
by: Margreet Schoorl, et al.
Published: (2015-06-01)

Neocytolysis: How to Get Rid of the Extra Erythrocytes Formed by Stress Erythropoiesis Upon Descent From High Altitude
by: Heimo Mairbäurl
Published: (2018-04-01)

Non-transfusion dependent thalassemia: translating evidence to guidelines
by: Afif R. Harb, et al.
Published: (2014-12-01)

PHARMACO-ECONOMICBENEFITS OF CORRECTION OF ANEMIA WITH CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR:HEMODIALYSIS VSHEMODIAFILTRATION
by: V. Novakivskyy
Published: (2017-03-01)

Achievement of renal anemia KDIGO targets by two different clinical strategies – a European hemodialysis multicenter analysis
by: Maciej Drozdz, et al.
Published: (2019-01-01)

Mild dyserythropoiesis and β-like globin gene expression imbalance due to the loss of histone chaperone ASF1B
by: Petros Papadopoulos, et al.
Published: (2020-10-01)

Usefulness of mid-week hemoglobin measurement for anemia management in patients undergoing hemodialysis: a retrospective cohort study
by: Soo Ya Bae, et al.
Published: (2019-08-01)

ATF4 Regulates MYB to Increase γ-Globin in Response to Loss of β-Globin
by: Mandy Y. Boontanrart, et al.
Published: (2020-08-01)

Regulating the Regulators: The Role of Histone Deacetylase 1 (HDAC1) in Erythropoiesis
by: Min Young Kim, et al.
Published: (2020-11-01)

High dose ESAs are associated with high iPTH levels in hemodialysis patients with end-stage kidney disease: a retrospective analysis
by: Lan eChen, et al.
Published: (2015-11-01)

Characteristics of erythropoiesis regulation in population living at high altitude
by: А В Makeshova, et al.
Published: (2004-11-01)

An examination of in vitro erythropoiesis by utilizing agents that mimic the in vitro activity of erythropoietin
by: Murthy, Sudish C.
Published: (2010)

The Effect of Erythropoiesis-Stimulating Agents on Platelet Aggregation in Peritoneal Dialysis Patients
by: Serkan Bakırdöğen, et al.
Published: (2019-11-01)

Physiological and Aberrant γ-Globin Transcription During Development
by: Gloria Barbarani, et al.
Published: (2021-04-01)

The Interplay between Drivers of Erythropoiesis and Iron Homeostasis in Rare Hereditary Anemias: Tipping the Balance
by: Simon Grootendorst, et al.
Published: (2021-02-01)

The role of reactive oxygen species during erythropoiesis: an in vitro model using TF-1 cells.
Published: (2009)

Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents
by: Jose Portolés, et al.
Published: (2021-03-01)

ERBP guideline on management of patients with diabetes and chronic kidney disease stage 3B or higher. Metformin for all?
by: Alberto Martínez-Castelao, et al.
Published: (2017-11-01)

Renal Cell Protection of Erythropoietin beyond Correcting The Anemia in Chronic Kidney Disease Patients
by: Hamid Nasri
Published: (2013-01-01)

The Role of the Nucleosome Remodeling and Histone Deacetylase (NuRD) Complex in Fetal γ-Globin Expression
by: Amaya, Maria
Published: (2013)

Stage Specific Expression Pattern of Alpha-Hemoglobin-Stabilizing-Protein (AHSP) Portrayed in Erythroblast Chronology
by: Julia Walczak, et al.
Published: (2020-06-01)

Primitive and definitive erythropoiesis in mammals
by: James ePalis
Published: (2014-01-01)

Effects of Roxadustat on the Anemia and Iron Metabolism of Patients Undergoing Peritoneal Dialysis
by: Keiji Hirai, et al.
Published: (2021-07-01)

Plasma erythropoietin level and heart failure in patients undergoing peritoneal dialysis: a cross-sectional study
by: Kohsuke Terada, et al.
Published: (2021-01-01)

The endoplasmic reticulum-associated mRNA-binding proteins ERBP1 and ERBP2 interact in bloodstream-form Trypanosoma brucei
by: Kathrin Bajak, et al.
Published: (2020-02-01)

Acai Extract Transiently Upregulates Erythropoietin by Inducing a Renal Hypoxic Condition in Mice
by: Shuichi Shibuya, et al.
Published: (2020-02-01)

Autophagy as a Regulatory Component of Erythropoiesis
by: Jieying Zhang, et al.
Published: (2015-02-01)

Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients
by: Luís Belo, et al.
Published: (2019-01-01)

Guía ERBP sobre la diabetes en la enfermedad renal crónica estadio 3B o mayor: ¿metformina para todos?
by: Alberto Martínez-Castelao, et al.
Published: (2017-11-01)

Anemia of chronic kidney disease: Protocol of study, management and referral to Nephrology
by: Aleix Cases, et al.
Published: (2018-01-01)

Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada
by: Mark Canney, et al.
Published: (2021-04-01)

The biogenesis of erythropoietin during inflammation
by: Leng, Henry Martin John
Published: (2018)

CONDITION OF THE ERYTHROID PART OF BLOOD SYSTEM AT STRESSED ANIMALS WITH HYPOTHYREOSIS
by: D. V. Garmayeva, et al.
Published: (2012-02-01)

Anaemia and heart failure: is there still a role for erythropoiesis-stimulating agents?
by: Massimo Volpe, et al.
Published: (2017-04-01)

How to select appropriate hemoglobin target levels on health-related quality of life and outcomes for patients with chronic kidney disease?
by: Filippo Salvati
Published: (2013-12-01)

THE ROLE OF SERUM TRANSFERRIN RECEPTORS MEASUREMENT
by: Bernarda Vogrin, et al.
Published: (2004-04-01)

Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006–2015)
by: Haesuk Park, et al.
Published: (2018-11-01)